Tasly Pharmaceutical Group Co (SHSE:600535) PE Ratio: 18.75 (As of Jul. 14, 2026) — 16% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600535 Tasly Pharmaceutical Group Co Ltd SHSE:600535
81 GF Score
Price ¥14.59
GF Value ¥15.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Tasly Pharmaceutical Group Co PE Ratio?

Tasly Pharmaceutical Group Co SHSE:600535 +1.46% 81 PE Ratio is 18.75 as of Jul. 14, 2026, which is 16% below its 10-year median of 22.27. GuruFocus rates SHSE:600535 with a GF Score™ of 81/100 and a GF Value™ of ¥15.06 (Fairly Valued). The stock has 1 warning sign investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-14), Tasly Pharmaceutical Group Co's share price is ¥14.59. Tasly Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.78. Therefore, Tasly Pharmaceutical Group Co's PE Ratio for today is 18.75.

Good Sign:

Tasly Pharmaceutical Group Co Ltd stock PE Ratio (=18.1) is close to 3-year low of 17.02.

During the past 13 years, Tasly Pharmaceutical Group Co's highest PE Ratio was 44.09. The lowest was 8.65. And the median was 22.27.

Tasly Pharmaceutical Group Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.78.

As of today (2026-07-14), Tasly Pharmaceutical Group Co's share price is ¥14.59. Tasly Pharmaceutical Group Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.75. Therefore, Tasly Pharmaceutical Group Co's PE Ratio without NRI ratio for today is 19.40.

During the past 13 years, Tasly Pharmaceutical Group Co's highest PE Ratio without NRI was 37.34. The lowest was 6.18. And the median was 19.47.

Tasly Pharmaceutical Group Co's EPS without NRI for the three months ended in Mar. 2026 was ¥0.24. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.75.

During the past 12 months, Tasly Pharmaceutical Group Co's average EPS without NRI Growth Rate was -9.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 3.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was -4.70% per year.

During the past 13 years, Tasly Pharmaceutical Group Co's highest 3-Year average EPS without NRI Growth Rate was 32.60% per year. The lowest was -22.80% per year. And the median was 11.60% per year.

Tasly Pharmaceutical Group Co's EPS (Basic) for the three months ended in Mar. 2026 was ¥0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.78.

Back to Basics: PE Ratio


Tasly Pharmaceutical Group Co  (SHSE:600535) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Tasly Pharmaceutical Group Co PE Ratio Related Terms


Tasly Pharmaceutical Group Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Tasly Pharmaceutical Group Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co PE Ratio Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.10 At Loss 23.64 22.59 20.36

Tasly Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.17 21.74 21.35 20.36 18.44

SHSE:600535 vs ZTS, UTHR: PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tasly Pharmaceutical Group Co PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Tasly Pharmaceutical Group Co's PE Ratio falls into.


SHSE:600535
81GF Score
Tasly Pharmaceutical Group Co Ltd SHSE:600535
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tasly Pharmaceutical Group Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Tasly Pharmaceutical Group Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=14.59/0.778
=18.75

Tasly Pharmaceutical Group Co's Share Price of today is ¥14.59.
Tasly Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.78.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 18.75 mean?
Tasly Pharmaceutical Group Co (SHSE:600535) has a PE Ratio of 18.75 as of Jul. 14, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 16% below median its historical median of 22.27. Over the past decade, Tasly Pharmaceutical Group Co's PE Ratio has ranged from 8.65 to 44.09.
Is Tasly Pharmaceutical Group Co's PE Ratio too high?
Tasly Pharmaceutical Group Co's current PE Ratio of 18.75 is 16% below median its 10-year median of 22.27. Over the past 10 years, this metric has ranged from a low of 8.65 to a high of 44.09. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's PE Ratio compare to ZTS and UTHR?
Tasly Pharmaceutical Group Co's PE Ratio of 18.75 can be compared against companies in the Drug Manufacturers industry. Historically, Tasly Pharmaceutical Group Co's own PE Ratio has ranged from 8.65 to 44.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Tasly Pharmaceutical Group Co and its competitors. Tasly Pharmaceutical Group Co's current PE Ratio is 18.75, which is 16% below median its own 10-year median of 22.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current PE Ratio is 18.75, which is 16% below median its 10-year median of 22.27. Tasly Pharmaceutical Group Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current PE Ratio is 18.75 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?

Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06. GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600535:

  • PE Ratio: 18.75 (16% below median its 10-year median of 22.27)
  • GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tasly Pharmaceutical Group Co Business Description

Address 2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
81GF Score

Get the complete analysis for SHSE:600535

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.59
Price
¥15.06
GF Value